Evidence map›Paper›PMID 32117286›Full record

ArticleFrontiers in immunology2020

Editorial: The Role of Complement in Tumors.

Barbara E Rolfe, Ruben Pio, Trent M Woodruff, Maciej M Markiewski, Helga D Manthey

Open access · goldAbstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Novel FABP4Cell death & disease · 2024
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Barbara E RolfeAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, Australia.
Ruben PioCenter for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
Trent M WoodruffSchool of Biomedical Sciences, The University of Queensland, Brisbane, QLD, Australia.
Maciej M MarkiewskiDepartment of Immunotherapeutics and Biotechnology, School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX, United States.
Helga D MantheyAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, Australia.
University of Queensland · AUTexas Tech University Health Sciences Center · USUniversidad de Navarra · ES

Funding

Targeting the Premetastatic Niche by Antiangiogenic ImmunotherapyR01CA190209 · NCI · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · PI MARKIEWSKI, MACIEJ MICHAL · 2016 to 2020
$1.7M
NCI NIH HHS R01 CA190209
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Complement ActivationAnimalsComplement System ProteinsCytotoxicity, ImmunologicHumansImmune Checkpoint InhibitorsImmunotherapyMolecular Targeted TherapyNeoplasmsComplement System ProteinsImmune Checkpoint InhibitorsC1qC3aC5aC5b-9cancercomplementcomplement regulatory proteinsmetastasis

Identifiers

PMID32117286
PMCPMC7027363
OpenAlexW3006505246

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.